Royce & Associates’s ClearPoint Neuro CLPT Stock Holding History

Royce & Associates’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-29,205	Closed	-$199K	–	881
2024 Q1	$199K	Sell	29,205 -23,860	-45%	-$167K	﹤0.01%	834
2023 Q4	$360K	Buy	+53,065	New	+$300K	﹤0.01%	813
2022 Q1	–	Sell	-17,700	Closed	-$199K	–	966
2021 Q4	$199K	Sell	17,700 -596,807	-97%	-$8.93M	﹤0.01%	946
2021 Q3	$10.9M	Buy	614,507 +523,607	+576%	+$9.82M	0.08%	385
2021 Q2	$1.74M	Buy	90,900 +35,800	+65%	+$692K	0.01%	780
2021 Q1	$1.17M	Buy	+55,100	New	+$1.18M	0.01%	836

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Royce & Associates's CLPT Position: Q2 2024 in Review

Royce & Associates sold out of ClearPoint Neuro (CLPT) in Q2 2024, closing a stake of 29,205 shares — an estimated $199K sold.

Royce & Associates first reported a position in CLPT in Q1 2021 and held it in 6 quarters. The position peaked at $10.9M in Q3 2021. 86 funds tracked by Wall St. Rank hold CLPT as of Q2 2024.

Royce & Associates reported no remaining ClearPoint Neuro position as of Q2 2024 after selling out during the quarter.
Royce & Associates sold 29,205 ClearPoint Neuro shares in Q2 2024, an estimated $199K.
Royce & Associates first reported a position in ClearPoint Neuro in Q1 2021 and held it in 6 quarters.
Royce & Associates's ClearPoint Neuro position peaked at $10.9M in Q3 2021.
86 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2024.

Based on Royce & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.